

Hepatopulmonary Syndrome in a Patient With Adenocarcinoma of the Colon Metastatic to the Liver and No Apparent Chronic Liver Disease

Brian Vila Auli,^a Diego Pérez García,^a Conrado Fernández Rodríguez,^b Pilar Bañuls Polo,^a and Julio Marín Pardo^a

^aServicio de Neumología, Hospital Clínico Universitario de Valencia, Valencia, Spain.

^bServicio de Medicina Interna, Hospital Clínico Universitario de Valencia, Valencia, Spain.

Hepatopulmonary syndrome consists of a clinical triad: arterial blood deoxygenation, intrapulmonary vasodilation, and liver disease. Both acute and chronic cases of this syndrome have been reported, and the most common cause is cirrhosis. The principle disease mechanism is dilation of the pulmonary blood vessels causing alterations in gas exchange. Increased pulmonary production of nitric acid has been implicated as the primary pathogenic mechanism of vasodilation although it has also been associated with imbalance between vasodilators and vasoconstrictors. We describe the case of a patient with hepatopulmonary syndrome and adenocarcinoma of the colon with metastases to a previously healthy liver.

Key words: *Hepatopulmonary syndrome. Pulmonary vasodilation. Liver disease. Adenocarcinoma of the colon.*

Síndrome hepatopulmonar en paciente con adenocarcinoma de colon con metástasis hepáticas y sin hepatopatía crónica conocida

El síndrome hepatopulmonar comprende una tríada clínica caracterizada por desoxigenación arterial, dilataciones vasculares intrapulmonares y hepatopatía. Se han descrito tanto casos agudos como crónicos, y la causa más frecuente es la cirrosis. El mecanismo fisiopatológico principal es la dilatación de los vasos pulmonares, que produce una alteración del intercambio gaseoso. Se ha implicado la mayor producción pulmonar de óxido nítrico como mecanismo patogénico principal de la vasodilatación, aunque también se ha relacionado el desequilibrio entre sustancias vasodilatadoras y vasoconstrictoras. Describimos un caso en el que se produjo un síndrome hepatopulmonar en un paciente afectado de un adenocarcinoma de colon con metástasis hepáticas en un hígado previamente sano.

Palabras clave: *Síndrome hepatopulmonar. Vasodilatación pulmonar. Hepatopatía. Adenocarcinoma de colon.*

Introduction

Hepatopulmonary syndrome is a clinical triad of arterial blood deoxygenation, intrapulmonary vasodilation, and liver disease.¹ The most common liver disorder is cirrhosis of any etiology, and the most common cause is alcohol abuse.² Abnormal gas exchange in a patient with liver disease may be a sign of this syndrome. If hepatopulmonary syndrome is suspected, measuring the alveolar-arterial oxygen partial pressure gradient is a more sensitive diagnostic technique than analysis of hypoxemia or carbon monoxide diffusion.^{3,4} The principal alteration involved in the syndrome is dilation of pre- and postcapillary lung vessels, causing mixed venous blood to reach the pulmonary veins too quickly. Also apparent is loss or absence of pulmonary vascular tone and hypoxic vasoconstriction.^{5,6} Diverse

substances have been implicated, the most important one being increased nitric oxide.⁷ A hyperkinetic circulatory state—high cardiac index and low pulmonary and systemic vascular resistance—is associated with liver cirrhosis and moderate to severe hepatopulmonary syndrome.

We report a case of hepatopulmonary syndrome in a man with adenocarcinoma of the colon and multiple metastases to the liver. Fifteen months prior to diagnosis, the patient had been evaluated for liver enzyme abnormalities secondary to taking antiinflammatory drugs. There was no evidence of chronic liver disease at that time.

Case Description

The patient was a 60-year-old retired office worker and nonsmoker with a history of hyperuricemia, high blood pressure, and polymyalgia rheumatica that had been diagnosed 2 years earlier. Fifteen months prior to hospitalization during an episode of gouty arthritis that was treated with colchicine, allopurinol, and diclofenac sodium, abnormal liver function was detected: aspartate aminotransferase level was 47 U/L (normal, 1 to 37 U/L), alanine aminotransferase was 69 U/L (normal, 1 to 41 U/L),

Correspondence: Dr. B. Vila.
Hospital Clínico Universitario.
Avda. Vicente Blasco Ibáñez, 17. 46010 Valencia. España.
E-mail: brianvila@mixmail.com

Manuscript received November 7, 2005. Accepted for publication December 27, 2005.

and γ -glutamyl transpeptidase was 165 U/L (normal, 10 to 49 U/L). Hepatitis serology was negative for hepatitis B surface antigen, hepatitis B core antibodies, hepatitis B antibodies (0.0 U/L), hepatitis C antibodies, and hepatitis A immunoglobulin M antibodies. Liver sonogram images and indocyanine green clearance were normal. After withdrawal of medication, drug-induced alterations returned to normal. The patient came to our emergency department after a month of asthenia, anorexia, weight loss of 6 kg, abnormal intestinal activity, progressive dyspnea to the point of fatigue at moderate exercise (walking 20 m), dry cough, and occasional fever. Arterial blood gas analysis (fraction of inspired oxygen, 0.21) revealed a pH of 7.49, PaO₂ of 57 mmHg, PaCO₂ of 27 mmHg, and bicarbonate (HCO₃⁻) of 20.6 mmol/L. The patient was referred to our outpatient clinic, where a computed tomography (CT) scan of the chest and upper abdomen was requested. Twenty-five days later, he returned for the CT scan, after which he made a second visit to the emergency department complaining of increased dyspnea that limited his ability to drink a glass of water. He was admitted for partial respiratory failure and multiple hypodense lesions in both lobes of the liver indicative of diffuse metastatic infiltration (Figure 1); arterial blood gas analysis (inspired oxygen fraction, 0.21) revealed a pH of 7.50, PaO₂ of 45 mmHg, PaCO₂ of 26 mmHg, and HCO₃⁻ of 20 mmol/L. Physical examination showed a temperature of 37°C, blood pressure of 110/50 mmHg, respiratory rate of 28 breaths/min. with no platypnea, and heart rate of 110 beats/min. Thorough cardiopulmonary auscultation detected no abnormalities. Telangiectasia was observed on the patient's face, torso, and upper limbs and was especially apparent on the palms (Figure 2) and chest. Liver function tests were carried out. Plasma biochemistry showed an aminotransferase level of 57 U/L; alanine amino transferase, 42 U/L; γ -glutamyl transpeptidase, 252 U/L; lactate dehydrogenase, 1428 U/L (normal, 240-480); total proteins, 7 g/dL; albumin, 3.4 g/dL; total bilirubin, 1.1 mg/dL; urea, 37 mg/dL, creatinine, 1.0 mg/dL; carcinoembryonic antigen, of 4645 ng/mL (normal, 0-6); and carbohydrate antigen 19.9, less than 5000 U/mL (normal, 0-37). Coagulation tests showed a prothrombin time of 16 seconds, a Quick index of 65%, and a fibrinogen level of 9.9 g/L. A hemogram showed total leukocytes of 10200 cells/ μ L; 73.3% were polymorphonuclear cells, 17.2% were lymphocytes, and 9% were monocytes. Colonoscopy revealed a mass 30 cm from the anus. A biopsy was performed and the mass was identified as infiltrating adenocarcinoma. Fine needle aspiration of the hepatic lesions was performed and cytologic evaluation indicated they were adenocarcinoma metastases. Assessment of the hypoxemia was concluded with a ventilation-perfusion scintigram, which showed a pattern suggesting low probability of pulmonary thromboembolism, and a high resolution spiral CT scan, which revealed small bronchiectases in both lung bases. Lung function test results were normal: forced vital capacity was 3.04 L (82.4%), forced expiratory volume in 1 second was 2.61 L (92.7% of predicted), the ratio of these parameters was 0.85, and the ratio of carbon monoxide diffusing capacity to alveolar volume was 1.24 mmol/min/kPa (99.5%). Arterial blood gas values measured in supine decubitus and sitting positions showed a decrease of 10% in PaO₂. Contrast-enhanced transthoracic echocardiography revealed microbubbles in the left heart chambers appearing between the third and fourth beats after they were visualized in the right chambers. Magnetic resonance angiography produced normal images.

The patient's condition deteriorated. Gas exchange worsened and systolic blood pressure progressively decreased to 86 mmHg despite cessation of antihypertensive treatment. Moreover, carcinoembryonic antigen levels rose to 14533 ng/mL.




Figure 1. Computed tomography image of the abdomen showing extensive metastases to the liver.



Figure 2. Telangiectasia on hands.

Discussion

Hepatopulmonary syndrome is associated with acute⁹ as well as chronic liver disease. In some cases—for example, in noncirrhotic portal hypertension—the hepatic parenchyma may not be involved. Altered metabolism or clearance of vasoactive substances secondary to liver failure or portal hypertension may produce a decrease in vasoconstrictor substances and an increase in vasodilator substances. The most important mechanism in pulmonary vasodilation is believed to be increased levels of nitric oxide synthetase in the endothelium of pulmonary vessels.⁷ Other vasodilator substances that potentially may be involved are atrial natriuretic peptide, platelet activating factor, vasoactive intestinal peptide, estrogens, glucagon, and prostaglandins. Levels of vasoconstrictor substances, such as endothelin I and serotonin, may decrease, thus contributing to vasodilation of pulmonary microcirculation. The difficulty in diagnosing this syndrome lies in the nonspecific nature of its symptoms. The most frequent symptom is dyspnea—with cyanosis, clubbing, and spider angioma. Although the most characteristic symptom is platypnea

(dyspnea on standing up from a recumbent position), it does not manifest in all patients. Exertional dyspnea appears during the natural course of cirrhosis, but only in certain cases is it associated with hepatopulmonary syndrome.¹ However, platypnea and orthodeoxia (decrease in $\text{PaO}_2 \geq 5\%$ or ≥ 4 mm Hg upon standing up from a recumbent position) are common observations in patients with hepatopulmonary syndrome and indicate a greater shunt in the lung bases, which become more perfused when the individual is standing.⁵ Hypoxemia with respiratory alkalosis demonstrated by arterial blood gas analysis should arouse suspicion of this syndrome. In cirrhosis this is a common finding, such that calculation of the alveolar-arterial oxygen partial pressure gradient¹⁰ and testing for the presence of orthodeoxia are essential. Lung function test results are usually normal, with the exception of reduced diffusing capacity. Dilation causes accelerated blood flow through the pulmonary capillaries, leaving insufficient time for gas exchange; therefore diffusing capacity is diminished even though there are no changes in the alveolointerstitial membrane. Transthoracic echocardiography with agitated saline or indocyanine green contrast enhancement, a noninvasive technique that enables detection of intrapulmonary vascular dilation, is the most sensitive technique for detecting pulmonary vasodilation.¹¹ Microbubbles can be visualized in the left heart chambers between the third and sixth beats after they have been observed in the right chambers. This technique can determine from exactly which pulmonary vein the bubbles are issuing.¹² If the bubbles are seen before the third beat, diagnoses of cardiac disease and large thoracic vessel disease characterized by right-to-left shunt must be ruled out.¹³ The microbubbles that pass through normal pulmonary circulation are so small (8-15 μm) that they are trapped and dissolved before entering the left heart chambers. It should be noted that a considerable number of cirrhosis patients have positive echocardiograms but normal blood gas findings; the prognosis for such patients is unknown.¹⁴ Another diagnostic technique is ventilation-perfusion scintigraphy performed with technetium 99m macroaggregated albumin; uptake is observed if there is a right-to-left shunt in the brain, kidneys, liver, bone, or spleen. However, cardiac and pulmonary shunts cannot be distinguished with this technique and it is less sensitive than transthoracic echocardiography.¹¹ Pulmonary angiography, now in disuse, will detect pulmonary vasodilation, although no abnormalities may be present.¹⁰ Severity of liver dysfunction,⁸ esophageal varices,^{15,16} and spider angioma⁴ is believed to be associated with the hemodynamic alterations characteristic of liver cirrhosis, but not with ascitics or liver encephalopathy.⁸

The case we report is uncommon because it involved detection by contrast-enhanced transthoracic echocardiography of intrapulmonary vasodilation associated with metastases from an adenocarcinoma of the colon to a previously healthy liver. Lee and Lepler¹⁷ reported the case of a female patient with metastatic carcinoma affecting the liver and associated with vasoactive substances secreted by the carcinoid tumor.

Teramoto et al¹⁸ hypothesized an association of nitric oxide with pulmonary vasodilation. The case we describe presented both pulmonary and systemic vasodilation—reflected by expression of spider angioma and a decrease in arterial blood pressure despite the withdrawal of medication. The clinical picture suggested generalized vasodilation and hyperdynamic circulation. These symptoms could be caused by a vasodilator substance secreted by the tumor or by a vasodilator-vasoconstrictor imbalance associated with the extensive metastatic involvement of the liver.

REFERENCES

1. Rodríguez-Roisin R, Krowka MJ, Hervé PH, Fallon MB, on behalf of the ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-vascular disorders (PHD). *Eur Respir J*. 2004;24:861-80.
2. Schenk P, Schöniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Müller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. *Gastroenterology*. 2003;125:1042-52.
3. Lima B, França A, Pazin-Filho A, Araújo W, Martínez JA, Maciel B, et al. Frequency, clinical characteristics, and respiratory parameters of hepatopulmonary syndrome. *Mayo Clin Proc*. 2004;79:42-8.
4. Schenk P, Fuhrmann V, Madl C, Funk G, Lehr S, Kandel O, et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. *Gut*. 2002;51:853-9.
5. Gómez FP, Mantínez-Pallí G, Barberà JA, Roca J, Navasa M, Rodríguez-Roisin R. Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. *Hepatology*. 2004;40:660-6.
6. Agustí A, Roca J, Bosch J, Rodríguez-Roisin R. The lung in patients with cirrhosis. *J Hepatol*. 1990;10:251-7.
7. Carter EP, Hartsfield CL, Miyazono M, Jakkula M, Morris KG, McMurtry IF. Regulation of heme oxygenase-1 by nitric oxide during hepatopulmonary syndrome. *Am J Physiol Lung Cell Mol Physiol*. 2002;283:346-53.
8. Alonso JL, Zozaya JM, García JL, Olaz-Preciado F, Estébanez Estébanez C, Berjón-Reyero J. Síndrome hepatopulmonar: relación con el grado de disfunción hepática y el trastorno hemodinámico de la cirrosis hepática. *Med Clín (Barc)*. 2004;123:721-5.
9. Regev A, Yeshurun M, Rodríguez M, Sagie A, Neff GW, Molina EG, et al. Transient hepatopulmonary syndrome in a patient with acute hepatitis A. *J Viral Hepat*. 2001;8:83-6.
10. Mohamed R, Freeman JW, Guest PJ, Davies MK, Neuberger JM. Pulmonary gas exchange abnormalities in liver transplant candidates. *Liver Transpl*. 2002;8:802-8.
11. Abrams GA, Jaffe CC, Hoffer PB, Binder HJ, Fallon MB. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. *Gastroenterology*. 1995;109:1283-8.
12. Krowka MJ, Cortese DA. Hepatopulmonary syndrome. Current concepts in diagnostic and therapeutic considerations. *Chest*. 1994;105:1528-37.
13. Cheng TO. Platypnea-orthodeoxia syndrome: etiology, differential diagnosis, and management. *Cathet Cardiovasc Interv*. 1999;47:64-6.
14. Krowka MJ, Tajik AJ, Dickson ER, Wiesner RH, Cortese DA. Intrapulmonary vascular dilatations (IPVD) in liver transplant candidates: screening by two-dimensional contrast-enhanced echocardiography. *Chest*. 1990;97:1165-70.
15. Caruso G, Catalano D. Esophageal varices and hepato-pulmonary syndrome in liver cirrhosis. *J Hepatol*. 1991;12:262-3.
16. Edel ES, Cortese DA, Krowka MJ, Rehder K. Severe hypoxemia and liver disease. *Am Rev Respir Dis*. 1989;140:1631-5.
17. Lee DF, Lepler LS. Severe intrapulmonary shunting associated with metastatic carcinoid. *Chest*. 1999;115:1203-7.
18. Terramoto S, Matsuse T, Ouchi Y. Carcinoid-related intrapulmonary shunting may be associated with increased production of nitric oxide. *Chest*. 1999;116:1838.